Aluminum Oxide Barium Carbonate Carbon Disulfide C
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Barium Carbonate Carbon Disulfide C
- Multi-Component Homeopathic Formulation: Insufficient Data for Drug Repurposing Evaluation
Multi-Component Homeopathic Formulation: Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This submission contains a 17-ingredient compound (including Conium maculatum, Datura stramonium, Mandragora officinarum, Mercurius solubilis, and Naja naja venom), consistent with a homeopathic or naturopathic preparation. The TxGNN pipeline returned no predicted indications for this formulation, as it could not be resolved to a single DrugBank entity. There are currently 0 clinical trials and 0 publications linked to this compound as a unit; no evidence package could be assembled.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no candidates) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only; in this case, not even a model prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why This Prediction Could Not Be Generated
The query string submitted to the pipeline was not a single active pharmaceutical ingredient (API) but a semicolon-delimited list of 17 substances:
Aluminum Oxide · Barium Carbonate · Carbon Disulfide · Conium maculatum Flowering Top · Datura stramonium · Egg Phospholipids · Helleborus niger Root · Lycopodium clavatum Spore · Mandragora officinarum Root · Mercurius Solubilis · Naja naja Venom · Picric Acid · Platinum · Silicon Dioxide · Sulfuric Acid · Sus scrofa Cerebrum · Zinc Phosphide
Several of these components — Conium maculatum, Datura stramonium, Helleborus niger, Mandragora officinarum, Mercurius solubilis, and Lycopodium clavatum — are classical ingredients in homeopathic pharmacopoeia. Others (Picric Acid, Carbon Disulfide, Zinc Phosphide, Naja naja Venom) are individually classified as toxic substances. The combination does not correspond to any approved pharmaceutical product in the DrugBank or TFDA databases.
Because TxGNN maps drug nodes via DrugBank IDs and the entire formulation resolved to drugbank_id: null, the knowledge-graph and deep-learning prediction stages both returned empty results. No mechanistic explanation can be offered for a drug repurposing hypothesis that was never generated.
Clinical Trial Evidence
Currently no related clinical trials registered for this formulation as a unit.
Literature Evidence
Currently no related literature available for this formulation as a unit.
US Market Information
This formulation holds no NDA or equivalent authorization. It is not marketed in the United States.
Safety Considerations
Several individual components of this formulation carry significant independent toxicity concerns:
- Datura stramonium (jimsonweed): anticholinergic alkaloids (scopolamine, atropine); narrow therapeutic–toxic window.
- Conium maculatum (poison hemlock): coniine alkaloids; neuromuscular blockade risk.
- Mandragora officinarum (mandrake root): tropane alkaloids; anticholinergic toxidrome.
- Naja naja venom (Indian cobra): neurotoxic and cytotoxic peptides.
- Zinc Phosphide: releases phosphine gas on contact with moisture; acutely toxic.
- Carbon Disulfide: neurotoxic solvent; hepatotoxic and nephrotoxic.
- Picric Acid: explosive oxidizer; skin and mucosal sensitiser.
- Mercurius Solubilis: inorganic mercury compound; nephrotoxic and neurotoxic.
No formal DDI data, contraindication list, or regulatory warning label exists for the combined formulation. Any clinical use of individual components would require independent safety assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline requires a single, DrugBank-resolvable API to generate drug repurposing predictions. This submission is a multi-ingredient formulation with no DrugBank node, no regulatory approval record, and no existing evidence base; the pipeline produced zero candidates, and several individual ingredients carry acute toxicity profiles that preclude expedited advancement.
To proceed, the following is needed:
- Identify the intended active ingredient: If one specific component is the candidate of interest (e.g., an alkaloid from Datura stramonium such as scopolamine, or a purified peptide from Naja naja venom), resubmit that single INN to the pipeline.
- Obtain a DrugBank ID: Map the candidate API to DrugBank before TxGNN scoring can be performed.
- Clarify the regulatory classification: Determine whether this formulation is submitted as a homeopathic product, a botanical drug, or a conventional pharmaceutical — each has a different regulatory pathway.
- Conduct individual-component toxicity review: Before any clinical hypothesis is formed, a full toxicological profile of each ingredient must be reviewed to establish a minimum safety basis.
- Do not proceed with any clinical hypothesis based on this Evidence Pack alone. The current data state is insufficient for any repurposing evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.